OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
June 03, 2021
Through the acquisition, Aceto can now offer its customers support throughout the drug development process and access to North American manufacturing for APIs and advanced intermediates.
June 02, 2021
The companies are expanding their collaboration to extend the drug substance manufacturing of Moderna’s COVID-19 vaccine with the addition of a new manufacturing line at Lonza’s Geleen, Netherlands, site.
June 01, 2021
Expected to be completed by 2022, the new addition is part of the Samsung Biologics’ long-term strategy to become a fully integrated global biopharmaceutical company.
May 19, 2021
Colorcon’s new suite will provide clients with capabilities to develop prototype tablets or capsule dosage forms when API quantity is limited or the API potency requires a higher level of protection.
April 29, 2021
Moderna’s investments will double the formulation fill/finish and drug substance manufacturing of its vaccine to up to three billion doses in 2022 at various manufacturing sites.
April 13, 2021
Catalent’s new mammalian cell culture suites in Madison, Wis. use single-use bioreactor systems for CGMP clinical and commercial manufacturing.
April 03, 2021
Intensified and distributed manufacturing approaches create flexible, local capacity.
February 18, 2021
The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.
Cascade began production on new facilities to manufacture APIs for clinical and commercial GMP production.
February 17, 2021
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.